Literature summary for 3.4.21.106 extracted from

Tripathi, M.; Nandana, S.; Yamashita, H.; Ganesan, R.; Kirchhofer, D.; Quaranta, V.
Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression (2008), J. Biol. Chem., 283, 30576-30584.

Search for more literature for 3.4.21.106

Application

Application	Comment	Organism
medicine	direct cleavage of Laminin-332 may be one mechanism by which hepsin promotes prostate tumor progression and metastasis, possibly by up-regulating prostate cancer cell motility	Homo sapiens

Protein Variants

Protein Variants	Comment	Organism
additional information	hepsin-overexpressing LNCaP prostate cancer cells also exhibit increased migration on Laminin-332	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
Glu-Gly-Arg-chloromethyl ketone	irreversible covalent inhibitor	Homo sapiens
hepatocyte growth factor activator inhibitor-1-derived Kunitz domain inhibitor	KD1, inhibits cleavage of laminin-332 in a dose-dependent manner	Homo sapiens

Localization

Localization	Comment	Organism	GeneOntology No.	Textmining

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
laminin-332 + H2O	by Western blotting and mass spectrometry, it is shown that hepsin cleaves the beta3 chain of rat Laminin-332. N-terminal sequencing identifies the cleavage site at beta3 Arg245, in a sequence context (SQLR245 cleavage LQGSCFC) conserved among species and in remarkable agreement with reported consensus target sequences for hepsin activity	Homo sapiens	?	-	?

Synonyms

Synonyms	Comment	Organism
hepsin	-	Homo sapiens

Temperature Optimum [°C]

Temperature Optimum [°C]	Temperature Optimum Maximum [°C]	Comment	Organism
37	-	assay at	Homo sapiens

pH Optimum

pH Optimum Minimum	pH Optimum Maximum	Comment	Organism
7.5	-	assay at	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)